Traitement par agent stimulant l’érythropoïèse, une double problématique

Bohlius, 2010, Twist and shout: one decade of meta-analyses of erythropoiesis-stimulating agents in cancer patients, Acta Haematol, 125, 55, 10.1159/000318897 Bohlius, 2005, Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis, J Natl Cancer Inst, 97, 489, 10.1093/jnci/dji087 Méric, 2005, Anémie chez les patients atteints de cancer pulmonaire, Bull Cancer, 92, 439 Henke, 2003, Erythropoietin to treat head and neck cancer patients with anemia undergoing radiotherapy: randomised double-blind, placebo-controlled trial, Lancet, 362, 1255, 10.1016/S0140-6736(03)14567-9 Leyland-Jones, 2003, Breast cancer trial with erythropoietin terminated unexpectedly, Lancet Oncol, 8, 459, 10.1016/S1470-2045(03)01163-X Overgaard, 2005, Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial, Lancet Oncol, 6, 757, 10.1016/S1470-2045(05)70292-8 Il est d’ailleurs intéressant de noter qu’une réponse insuffisante aux ASE associée à une mortalité accrue a également été signalée chez des patients insuffisants rénaux bénéficiaires d’un traitement par ASE, et ce indépendamment des autres facteurs de risque. Tonnelli, 2009, Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis, CMAJ, 180, E62, 10.1503/cmaj.090470 Bennett, 2008, Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia, JAMA, 299, 914, 10.1001/jama.299.8.914 Bohlius, 2006, Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients, J Natl Cancer Inst, 98, 708, 10.1093/jnci/djj189 Hardee, 2006, Erythropoietin biology in cancer, Clin Cancer Res, 12, 332, 10.1158/1078-0432.CCR-05-1771 Aapro, 2009, Managing cancer-related anaemia in congruence with the EORTC guidelines is an independent predictor of haemoglobin outcome: initial evidence from the RESPOND study, Eur J Cancer, 45, 8, 10.1016/j.ejca.2008.09.036 Glaspy, 2010, Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes, British Journal of Cancer, 102, 301, 10.1038/sj.bjc.6605498 Hardee, 2005, Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis, Br J Cancer, 93, 1350, 10.1038/sj.bjc.6602846